SecBot SecBot

GRCE drug pipeline

Grace Therapeutics, Inc. · 1 rated drug
$1.75
−3.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±10.2%
1-day, median of 10 events
IV rank
No data
No current options data
Rated drugs
1
1 bearish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 1 (discontinued)
Time to marketNot applicable — program discontinued

GTx-101 bupivacaine topical spray Updated Sep 12

What to watch

GTx-101 has been formally discontinued and written off. Investors should ignore this asset entirely, Grace Therapeutics' stock is now a pure binary play on the GTx-104 NDA resubmission timeline and FDA outcome. Monitor the company's progress on manufacturing remediation and stability data milestones for GTx-104, not GTx-101.

Bull case
  • The PK bridging study met all primary outcome measures, demonstrating that GTx-101 could deliver bupivacaine systemically via topical application, potentially offering a needle-free alternative for PHN pain management.
  • The bioadhesive film-forming polymer platform could have been applicable to other drugs, though this is now moot given the discontinuation.
Bear case
  • GTx-101 has been formally discontinued, Grace Therapeutics recorded a $13.5M non-cash impairment of IPR&D for GTx-101 and GTx-102 in Q1 FY2027, confirming the program is dead.
  • The company has pivoted entirely to GTx-104, which itself faces regulatory uncertainty after receiving an FDA Complete Response Letter in April 2026.
  • GTx-101 never advanced beyond Phase 1 studies, so its clinical and commercial viability was never established.

Other drugs in filings and trials

no drug report yet
  • GTx-104 Last: Orphan drug designation · Jul 28, 2026

Past FDA events & how the stock moved

10 events
DateDrugEvent1 day5 days
Jul 28, 2026GTx-104Orphan drug designation−9.6%−5.2%
Jun 18, 2026GTx-104Orphan drug designation+1.8%+7.2%
Apr 23, 2026GTx-104Orphan drug designation−46.6%−48.0%
Apr 23, 2026GTx-104PDUFA decision−46.6%−48.0%
Apr 23, 2026GTx-104NDA filed−46.6%−48.0%
Apr 23, 2026GTx-104Complete response letter−46.6%−48.0%
Apr 1, 2026GTx-104Complete response letter+10.8%−21.8%
Feb 12, 2026GTx-104NDA filed+0.6%+8.1%
Nov 13, 2025GTx-104Orphan drug designation+1.0%+3.6%
Aug 22, 2025GTx-104NDA filed−1.5%−8.2%